• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×
  • 05 Jun 17
title

THE NAKED FUND MANAGER - What changes are needed post Fusionex fiasco

  • 2867 views
The Naked Fund Manager

UK-focused Small and Mid-cap fund manager.

 
fusionex slumps after announcement to delist from AIM may 2017
Strap line

The AIM Rules around delisting need to be improved if minority investors are to be properly protected

Companies: Fusionex International


Body

Afternoon all,

 

Apologies ahead of time but as a holder of a small piece of Fusionex I’ve decided to go on a bit of a rant below about the parlous situation in which we find ourselves.

 

Fusionex

As I’ve mentioned above, I picked up a small piece of FXI a couple of months ago and was just starting to do some more involved work when the storm broke the Friday before last. Luckily my investment was really quite small so far, so the damage to the fund has been minimal.

 

However, it serves to highlight that there is much work to be done on the corporate governance side if we are going to reduce the frequency of these events.

 

 

What happened?

The shares had spiked up back in 2014 after an IPO around end 2012, but had since come off to the point where they were down around 28% from their IPO level by the time Fusionex announced a disappointing set of FY 2016 Results in March 2017.

 

Top line growth had continued, rising over 22% in 2016, but admin expenses rose dramatically over the period, more than doubling from 35m to over 72m Malaysian Ringgit (MYR), as the company repositioned from a licence model to be subscription-based. This turned a healthy 26% growth in Gross Profit to a minus 84% slump in PBT, from MYR 28m in 2015 down to just MYR 4.5m in 2016.

 

 

fusionex share price since ipo


 

As you would expect, the shares slid off the back of these results, falling a further 10%. At this point, they were starting to look attractive as tangible progress was being made in the business and the transition pains in re-focussing on its GIANT product appeared behind them. However, to my mind, the level of discounting applied by the market was broadly fair because Fusionex had yet to properly deliver on its new strategic direction.

 

As an investor, there was a decent opportunity for high returns as GIANT started to deliver and this return looked attractive, yet fair, when balanced with the risks involved.

 

 

CEO decides to delist (and probably screw minorities)

Late in the afternoon on Friday 26th May, the company announced it was planning to delist from the exchange because it was disappointed with the amount of value the market was ascribing to the business, despite all the progress that was being made.

 

It’s difficult for that kind of statement to pass the red face test when held up against an 84% slump in profits recently reported.

 

The announcement precipitated a 70% fall in share price as the investors contemplated the prospect of holding shares in a private company that will be tricky to sell at anything like a reasonable price.

 

Furthermore, most funds that have a stake won’t have a remit to hold unlisted shares and therefore become forced sellers.

 

 

Unfortunately, Fusionex holds all the cards

Under the AIM Rules, a company can pass a delisting resolution with 75% of the vote that turn up on the day (in person or by proxy). Between the CEO (41% equity), another significant employee (13%) and a founding investor (5%), the resolution already has the backing of 59% of shareholders. On that basis, minority investors would need the turnout to exceed 78% and all other votes to go against the resolution for it to be stopped.

 

The unfortunate reality is that a turnout that high is unlikely in a company that has a relatively high level of retail ownership.

 

 

Caveat emptor

This is an incredibly disappointing outcome and is another example of minority investors being poorly served by a company and by the AIM Rules.

 

Investors should have known the risks as there is always a chance minorities can be squeezed out when there is a concentration of ownership as high as there was in this case. I would go so far as to say that investors did know the risks, and this was one of the reasons the market was discounting Fusionex higher than the CEO would have liked.

 

On a personal level, I should have considered the risks to my stake as a minority in more detail before making my initial investment, but again, the lack of sufficient due diligence is a reason the size of my initial investment was small.

 

 

Changes required to the AIM Rules

It seems clear to me that changes should be made to the AIM Rules in order to reduce the chances of this happening again. Fusionex looks like it can shortly be added to a long list of companies that have squeezed minority investors out unfairly.

 

The Quoted Companies Alliance (QCA) published a piece on this very subject back in 2009. It laid out a few potential solutions to better protect minority investors: 

 

  • One option that was proposed as a solution was to make the resolution only passable if 75% of total shareholders voted in favour, rather than just those that turned up. It does seem bizarre that minorities can be punished and a company delisted, not because 75% of shareholders vote for a resolution but because other less engaged minority investors fail to show up.

  • Another option would be to raise the threshold to 90% from 75%, although this option is not desirable in my opinion as there is more scope for unintended consequences.

 

If these black marks continue to amass against the track record of AIM markets, fewer investors (both retail and institutional) will want to invest, liquidity will deteriorate, and quality companies will choose other sources for capital when looking at the next stage of their growth.

 

The quality of companies on AIM has improved in recent years, but there are still many easy to implement changes that would significantly improve the market for all stakeholders.


 

-----

 

To read a brief outline of how I think about stocks, and what I aim to achieve in this blog, please check out my first blog where I set out my stall.

 

Recent blogs:

  • 5 Jun 17 - Why Labour's Manifesto needs a dose of reality
  • 30 May 17 - China shows Western Tech Giants might be stifling innovation
  • 8 May 17 - Why corporate chiefs are better leaders than politicians
  • 2 May 17 - Why the best businesses have great cash conversion
  • 10 Apr 17 - Platforms are taking over the world
  • 3 Apr 17 - Bingo player Jackpotjoy offers interesting upside...and risk
  • 27 Mar 17 - What Banks and Brokers can learn from Amazon
  • 20 Mar 17 - Why understanding behavioural finance is just as important as stock picking
  • 14 Mar 17 - What to make of Challenger Banks
  • 6 Mar 17 - CFD platforms still worth a look
  • 27 Feb 17 - Purplebricks US expansion: How big is the opportunity?
  • 20 Feb 17 - M&A - One reason why I’m still bullish on UK equities
  • 14 Feb 17 - Anatomy of a growth company
  • 6 Feb 17 - Roll-outs: the Good, the Bad and the Ugly
  • 30 Jan 17 - How MiFID II could hurt Small and Mid-caps
  • 23 Jan 17 - Why Pearson was an obvious value trap, and is Jackpotjoy worth a closer look?
  • 16 Jan 17 - How sustainable are current dividends
  • 8 Jan 17 - Implications of Trumponomics for equities
  • 18 Dec 16 - Millennials - Becoming the most important demographic
  • 12 Dec 16 - CFDs - Tough week but worth a closer look
  • 5 Dec 16 - Pension deficit dogs starting to look interesting
  • 28 Nov 16 - Setting out my stall...plus my thoughts on bond proxies 

Please Note: To be clear, I do not and will not ever give any advice. I will rarely mention individual stocks but when I do these will not be recommendations, instead just my thoughts at that point in time.

 


Body Two



Body Three

Body Four

Body Five

The information contained within this post is based on personal experience and opinion and should not be considered as a recommendation to trade nor financial advice.

More Content

More Content

Small Cap Breakfast

Companies: CHRT WYG TRX GROW SKIN ORM TOM FXI

Hybridan

Fusionex to beat expectations as new SME product makes big impact

Companies: Fusionex International

Research Tree

Fusionex shares collapse as company announces plans to delist

Companies: Fusionex International

Research Tree

Small Cap Breakfast

Companies: PEG IOF ESR FCR ITM FXI HDD MREO

Hybridan

Small Cap Breakfast

Companies: CRU PCIP DIAL MET XSG SMTP FXI BOOM INQO

Hybridan
next
 
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Acquisdata
      • Actinver
      • Actio Advisors
      • Asset TV
      • Astris Advisory
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In